11 Luborsky L. Principles of psychoanalytic psychotherapy: A manual for supportive/expressive treatment New York: Basic Books; 1984.
14 Gaston L, Thompson L, Gallagher D, Cournoyer L-G, Gagnon R. Alliance, technique, and their interactions in predicting outcome of behavioral, cognitive, and brief dynamic therapy. Psychotherapy Research. 1998;8(2):190-209.
2 Murray CJL, Lopez AD. The Global Burden of Disease. A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Cambridge, Massachussetts: Harvard University Press; 1997.
3 McCrone P, Dhanasiri S, Patel A, Knapp M, Lawton-Smith S. Paying the Price: The Cost of Mental Health Care in England to 2026. London: King's Fund; 2008.
Abbass A, Kisely S, Kroenke K Short-term psychodynamic psychotherapy for somatic disorders. Systematic review and meta-analysis of clinical trials. Psychother Psychosom. 2009;78(5):265-74. doi: 10.1159/000228247. Epub 2009 Jul 11. Review.
Abbass A, Sheldon A, Gyra J, Kalpin A Intensive short-term dynamic psychotherapy for DSM-IV personality disorders: a randomized controlled trial. J Nerv Ment Dis. 2008 Mar;196(3):211-6. doi: 10.1097/NMD.0b013e3181662ff0.
Abbass A, Town J, Driessen E Intensive short-term dynamic psychotherapy: a systematic review and meta-analysis of outcome research. Harv Rev Psychiatry. 2012 Mar-Apr;20(2):97-108. doi: 10.3109/10673229.2012.677347. Review. Erratum in: Harv Rev Psychiatry. 2013 Sep-Oct;21(5):280.
Abbass AA Intensive Short-Term Dynamic Psychotherapy of treatment-resistant depression: a pilot study. Depress Anxiety. 2006;23(7):449-52.
Barber JP, Crits-Christoph P, Luborsky L Effects of therapist adherence and competence on patient outcome in brief dynamic therapy. J Consult Clin Psychol. 1996 Jun;64(3):619-22.
Guilbert JJ The world health report 2002 - reducing risks, promoting healthy life. Educ Health (Abingdon). 2003 Jul;16(2):230.
Hilsenroth MJ, Ackerman SJ, Blagys MD, Baity MR, Mooney MA Short-term psychodynamic psychotherapy for depression: an examination of statistical, clinically significant, and technique-specific change. J Nerv Ment Dis. 2003 Jun;191(6):349-57.
Markowitz JC When should psychotherapy be the treatment of choice for major depressive disorder? Curr Psychiatry Rep. 2008 Dec;10(6):452-7. Review.
Simon GE, Ludman E, Unützer J, Bauer MS Design and implementation of a randomized trial evaluating systematic care for bipolar disorder. Bipolar Disord. 2002 Aug;4(4):226-36.
Stimpson N, Agrawal N, Lewis G Randomised controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression. Systematic review. Br J Psychiatry. 2002 Oct;181:284-94. Review.
Thomas CM, Morris S Cost of depression among adults in England in 2000. Br J Psychiatry. 2003 Dec;183:514-9.
Trivedi RB, Nieuwsma JA, Williams JW Jr Examination of the utility of psychotherapy for patients with treatment resistant depression: a systematic review. J Gen Intern Med. 2011 Jun;26(6):643-50. doi: 10.1007/s11606-010-1608-2. Epub 2010 Dec 24. Review.
Halifax Treatment Refractory Depression Trial: A Randomized Controlled Trial of Intensive Short-Term Dynamic Psychotherapy (ISTDP) Compared to Secondary Care Treatment as Usual
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
